Heidelberg Pharma AG receives milestone payment from partner Takeda
Heidelberg Pharma AG (FSE: HPHA, XETRA: HPHA) announced on 29 January 2026 that it has received a development‑milestone payment under the terms of its license agreement with Takeda Pharmaceutical Company. The payment is linked to the achievement of a clinical development milestone for Takeda’s investigational antibody‑drug conjugate (ADC) that employs Heidelberg Pharma’s Amanitin‑based Antibody‑Drug Conjugate (ATAC) technology.
The milestone payment confirms the progress of the licensed ADC candidate and provides additional financial support for Heidelberg Pharma’s ongoing research and development activities. The company, which specializes in novel cancer therapies and conducts research in pharmacology, drug metabolism, pharmacokinetics and molecular biology, continues to focus on the commercialization of its biopharmaceutical products in the German market.
Heidelberg Pharma’s share price closed at €2.82 on 27 January 2026, with a 52‑week high of €5.36 (5 June 2025) and a low of €2.15 (12 February 2025). The company’s market capitalisation is €138.48 million and its price‑to‑earnings ratio is –5.36, reflecting its status as a clinical‑stage biotech firm.
